<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">
  <title>WHO adds GLP-1RAs to essential medicines list</title>
</head>
<body>
  <a href="../../index.html">← Back to home</a>
  <h1>WHO adds GLP-1RAs to essential medicines list</h1>
  <ul>
<li>This has led analysts at GlobalData, parent company of Pharmaceutical Technology, to forecast that Saxenda will make just $135m in 2031 – down 91% from the $1.5bn sales seen at its peak in 2022.</li>
<li>Meanwhile, Trulicity also offers only a small price reduction, being sold at $987 instead of the $1079.77 charge for Mounjaro.</li>
<li>Generics to improve GLP-1RA accessibility The August 2025 US approval of Teva Pharmaceutical’s generic Saxenda has left Novo Nordisk’s version vulnerable to competition.</li>
<li>However, WHO raised concerns about the costs of both semaglutide and tirzepatide, which come with a hefty price tag of between $997 and $1349 for a one-month prescription in the US, which the agency warns could complicat</li>
<li>The World Health Organisation (WHO) has updated its model list of essential medicines (EML) to include four key obesity and type 2 diabetes (T2D) drugs.</li>
<li>The United Nations (UN) agency has added the glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists to the EML following a review from the</li>
<li>Saxenda is currently very similar in price to its more efficacious successor, semaglutide.</li>
</ul>
<p><a href="https://finance.yahoo.com/m/bb4b1ca7-94ec-368e-9014-307f68cd1bcb/who-adds-glp-1ras-to.html">Source</a> · 2025-09-08T17:59:13+00:00</p>
</body>
</html>